Data / Form D filings / Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp.: Form D filings
Medicenna Therapeutics Corp., a biotechnology company in Toronto, Ontario, Canada, filed 4 Form D notices with the SEC between 2020 and 2026. The latest, on July 6, 2026, reports $253,458 sold of a $2.3 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2 BLOOR STREET W SUITE 903, Toronto, Ontario, Canada, M4W 3
- Phone
- (604) 671-6673
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Canada (Federal Level)
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1807983
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | New notice | $2,343,400 | $253,458 | $2,089,942 | 3 | May 28, 2026 | sec.gov |
| May 14, 2024 | New notice | $14,587,404 | $14,550,000 | $37,404 | 1 | Apr 30, 2024 | sec.gov |
| Apr 20, 2020 | Amendment | $9,219,339 | $9,219,339 | 6 | Mar 17, 2020 | sec.gov | |
| Mar 30, 2020 | New notice | $6,717,542 | $6,717,542 | 4 | Mar 17, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Fahar Merchant | Executive Officer, Director | |
| David Hyman | Executive Officer | |
| Nageatte Ibrahim | Executive Officer | |
| Rosemina Merchant | Executive Officer | |
| Albert G. Beraldo | Director | |
| John Geltosky | Director | |
| Karim Lalji | Director | |
| Richard Sutin | Director | |
| Angelos Georgakis | Director |
Every Form D from the week of Jul 6, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Medicenna Therapeutics Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.